Search results for: 'Developments in Digital Biomanufacturing: Technology Growth Opportunities'

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping biomanufacturing, cell and gene therapy, precision immunotherapy, anti-infectives, and neurotherapeutics across oncology, infectious disease, nephrology, and neurodegenerative disease. It hi...

Europe’s life sciences sector is approaching a defining inflection point in 2026, as major regulatory and policy reforms converge to reshape pharma, diagnostics, life sciences IT, biotechnology, and the bioeconomy. Together, these frameworks open clear growth pathways across the value chain: the Clinical Trials Regulation (CTR) and European Health ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across recent technology advances across cell & gene therapies, immunotherapies, intelligent drug discovery approaches, automated biomanufacturing and microbiome sciences. The TOE also encompasses recent developments in proteomics, drug deliver...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across innovations in precision medicine, targeted drug delivery, RNA editing, biomanufacturing, cell and gene therapies. The research also comprises advances in single cell analysis, hybrid microbots, AI-powered diagnostic, bioprinting and non...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) covers insights across biomanufacturing, targeted drug delivery, imaging, precision medicine and biologics innovations.The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides actionable insights across new developments in prebiotics, immunology, oncology, cell and gene therapies, antibody therapies, and precision medicine approaches. The TOE also encompasses technology advances across the use of AI and ML in drug discovery a...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming AI-enabled discovery, precision diagnostics, cell engineering, targeted therapeutics, vaccines, and skin health across oncology, metabolic disease, rare disorders, neuropsychiatry, and ne...

Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, with reported cases having doubled since 1990. Today, CVDs account for 1 in 3 deaths worldwide, representing 32% of total global mortality, with heart attacks and ischemic strokes responsible for approximately 85% of these outcomes. The rising burden is stron...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) comprise innovation insights across antibody and cellular therapies. The study also encompasses recent innovations in liquid biopsy tests, drug delivery and drug discovery platforms.The Life Science, Health & Wellness TOE will feature disruptive technology advan...